Alkyl Amines Chemicals Limited (NSE: ALKYLAMINE | BSE: 506767)
Source: Alkyl Amines Chemicals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Alkyl Amines Chemicals Limited (AACL) operates as a leading global manufacturer and merchant supplier of aliphatic amines, amine specialty derivatives, and complex fine chemical building blocks. The company functions within the foundational layers of the industrial value chain, transforming basic chemical feedstocks—such as denatured ethyl alcohol, methanol, anhydrous ammonia, and industrial gases—into highly engineered chemical intermediates that serve as vital ingredients for pharmaceutical active pharmaceutical ingredients (APIs), crop protection chemistries, water treatment solutions, and rubber processing accelerators.
- Aliphatic Amines Portfolio: Encompasses methylamine derivatives (Monomethylamine, Dimethylamine, Trimethylamine) and ethylamine derivatives (Monoethylamine, Diethylamine, Triethylamine). These base chemistries are synthesized via vapor-phase catalytic reaction of alcohols with anhydrous ammonia.
- Downstream Amine Derivatives: Higher alkylamines, specialized amine hydrochlorides, quaternary ammonium compounds, and modified amine building blocks tailored for active pharmaceutical ingredient synthesis and agrochemical active formulations.
- High-Purity Acetonitrile & Specialty Solvents: Highly purified solvent grades utilized extensively in pharmaceutical chromatography (HPLC), DNA/RNA oligonucleotide synthesis, and specialty industrial separation processes.
- Customer Concentration Profile: In compliance with Ind AS 108 disclosures, the company maintains a well-diversified domestic and global customer franchise. No single external customer accounted for 10% or more of the company’s total revenue in either FY 2025-26 or FY 2024-25.
📋 Quick Facts / Company Snapshot: Alkyl Amines Chemicals Limited (NSE: ALKYLAMINE | BSE: 506767)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Alkyl Amines Chemicals Limited |
| Corporate Identity Number (CIN) | L99999MH1979PLC021796 |
| ISIN | INE150B01039 |
| Stock Exchange Listing | BSE Limited & National Stock Exchange of India Limited |
| Date of Incorporation / Founding Year | 1979 |
| Registered Office | 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai – 400 703, Maharashtra |
| Corporate Headquarters | 207A, Kakad Chambers, 132, Dr. Annie Besant Road, Worli, Mumbai – 400 018, Maharashtra |
| Telephone & Official IR Email | Tel: +91 22 6794 6600 | Email: legal@alkylamines.com |
| Chairman & Managing Director | Yogesh M. Kothari |
| Chief Financial Officer (CFO) | Kanchan A. Shinde |
| Company Secretary & Compliance Officer | Chintamani D. Thatte |
| Promoter & Holding Group | Yogesh M. Kothari and Promoter Group Entities (72.05% Equity Holding) |
| Industry / Sector Classification | Specialty Chemicals / Aliphatic Amines (NIC Code: 20119) |
| Total Employees / Workforce Split | 682 Permanent Employees, 15 Other Employees, 51 Permanent Workers, 924 Contractual Workers (Total Workforce: 1,672) |
| Workforce Turnover Rate | Permanent Employees: 13.78% (FY 2025-26) | Permanent Workers: 0.13% |
| Manufacturing Plants & Clean Energy Footprint | 3 Chemical Manufacturing Sites (Kurkumbh, Patalganga, Dahej) + 3 Solar Power Plants (Bhoom, Manwath, Talegadh) |
| Credit Rating & Agency | CRISIL AA-/Stable (Long-Term Facilities) & CRISIL A1+ (Short-Term Facilities) |
| Statutory Auditors | M/s. N. M. Raiji & Co., Chartered Accountants, Mumbai (FRN: 108296W) |
| Secretarial Auditor | Mr. Prashant S. Mehta, Practising Company Secretary, Mumbai (P Mehta & Associates) |
| Cost Auditors | M/s. Manish Shukla & Associates, Cost Accountants, Mumbai |
| Registrar and Share Transfer Agent (RTA) | MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), Mumbai |
🏢 The Corporate Identity: Alkyl Amines Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Alkyl Amines Chemicals Limited (AACL) operates as a leading global manufacturer and merchant supplier of aliphatic amines, amine specialty derivatives, and complex fine chemical building blocks. The company functions within the foundational layers of the industrial value chain, transforming basic chemical feedstocks—such as denatured ethyl alcohol, methanol, anhydrous ammonia, and industrial gases—into highly engineered chemical intermediates that serve as vital ingredients for pharmaceutical active pharmaceutical ingredients (APIs), crop protection chemistries, water treatment solutions, and rubber processing accelerators.
The company operates an integrated chemical synthesis model across continuous and multi-purpose batch manufacturing sites located strategically across western India. By leveraging proprietary catalytic synthesis developed through in-house research and development, Alkyl Amines captures domestic market leadership while exporting specialty solutions to regulated and semi-regulated chemical formulations markets globally across 39 nations.
The Founders, Promoters & Their Legacy
The enterprise was established in 1979 under the visionary stewardship of industrialist Yogesh M. Kothari, who serves as Chairman and Managing Director. Supported by experienced executive leadership, including Executive Director Kirat M. Patel and Executive Director Suneet Y. Kothari, the promoter group has maintained steady technological discipline and financial conservatism, resulting in a debt-free operational structure supported by internally generated cash reserves.
The promoter and promoter group hold an aggregate 72.05% equity stake in the company as of March 31, 2026, anchoring long-term strategic decision-making around continuous process intensification, environmental stewardship, and disciplined capital allocation.
The Journey: Corporate History & Key Milestones
From pioneering the domestic merchant manufacture of ethylamines and methylamines in India, the company has methodically scaled its operational capabilities, diversified product chemistries, and integrated green manufacturing systems across more than four decades of continuous enterprise.
- 1979: Incorporation of Alkyl Amines Chemicals Limited, initiating domestic commercialization of aliphatic amines.
- 1999: Expansion of technical and corporate governance leadership with key board inductions, laying the foundation for modern specialty derivative production.
- 2018: Implementation of the AACL Employees Stock Option Plan 2018 to align long-term organizational talent with corporate performance milestones.
- 2021: Execution of equity share sub-division on May 12, 2021, splitting the nominal face value of equity shares from ₹5 each into ₹2 each to enhance market liquidity.
- 2023: Recertification under the International Responsible Care® initiative administered in India by the Indian Chemical Council, valid through October 2026.
- 2025–2026: Commissioning of three captive solar power installations across Maharashtra and Gujarat, zero-liquid discharge effluent management implementation across sites, and expansion into specialty acetonitrile and custom synthesis platforms.
The Corporate Umbrella & Group Structure
Alkyl Amines Chemicals Limited functions as a standalone operating entity. The company does not have any subsidiary, associate, or joint venture company as of March 31, 2026. All corporate assets, manufacturing plants, R&D centers, and captive solar installations are held directly on the standalone balance sheet of the company, resulting in complete financial and operational alignment under a single corporate reporting umbrella.
⚙️ The Business Engine: Alkyl Amines Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
In accordance with Indian Accounting Standard (Ind AS) 108 Operating Segments, the company’s internal reporting reviewed by the Chief Operating Decision Maker (CODM)—identified as the Board of Directors—evaluates the business as a single unified primary operating segment: “Specialty Chemicals”. Within this core specialty chemical engine, the company monitors operational metrics across three primary product groupings: Aliphatic Amines, Amine Derivatives, and Specialty Chemicals / Amines.
| Business Portfolio Group | Gross Revenue (₹ Crores) | % Share of Total Revenue | Operational Focus & Key Chemistries |
|---|---|---|---|
| Aliphatic Amines | 684.22 | 44.55% | Methylamines (Mono, Di, Tri), Ethylamines (MEA, DEA, TEA) |
| Amine Derivatives | 471.06 | 30.67% | Downstream alkylated derivatives, functional salts, amino alcohols |
| Specialty Chemicals / Amines | 380.59 | 24.78% | High-purity Acetonitrile, complex cyclic amines, fine intermediates |
| Total Specialty Chemicals Engine | 1,535.86 | 100.00% | Consolidated Operational Manufacturing Platform |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
The company manufactures and markets a diverse portfolio of aliphatic amines and high-purity chemical derivatives engineered to exact customer specifications across continuous synthesis and specialized campaign production runs.
- Aliphatic Amines Portfolio: Encompasses methylamine derivatives (Monomethylamine, Dimethylamine, Trimethylamine) and ethylamine derivatives (Monoethylamine, Diethylamine, Triethylamine). These base chemistries are synthesized via vapor-phase catalytic reaction of alcohols with anhydrous ammonia.
- Downstream Amine Derivatives: Higher alkylamines, specialized amine hydrochlorides, quaternary ammonium compounds, and modified amine building blocks tailored for active pharmaceutical ingredient synthesis and agrochemical active formulations.
- High-Purity Acetonitrile & Specialty Solvents: Highly purified solvent grades utilized extensively in pharmaceutical chromatography (HPLC), DNA/RNA oligonucleotide synthesis, and specialty industrial separation processes.
- Customer Concentration Profile: In compliance with Ind AS 108 disclosures, the company maintains a well-diversified domestic and global customer franchise. No single external customer accounted for 10% or more of the company’s total revenue in either FY 2025-26 or FY 2024-25.
- Raw Material Consumption Architecture: During FY 2025-26, indigenous raw materials comprised ₹587.38 Crores (77.30% of total raw material consumption), while imported raw materials accounted for ₹172.49 Crores (22.70%). Raw material consumption was anchored by denatured ethyl alcohol, methanol, and other alcohols (₹358.58 Crores), industrial gases (₹154.28 Crores), and other specialized chemical feedstocks (₹247.01 Crores).
The Names You Know: Key Brands & Flagship Portfolio
While Alkyl Amines operates predominantly in the business-to-business (B2B) merchant chemical domain, its product nomenclature and high-grade technical chemical offerings function as benchmark specifications across pharmaceutical, life sciences, and industrial process industries.
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Methylamines (MMA, DMA, TMA) | Aliphatic Amines | Pharmaceutical synthesis, agrochemical intermediates, water treatment flocculants |
| Ethylamines (MEA, DEA, TEA) | Aliphatic Amines | Crop protection chemicals, rubber vulcanization accelerators, polyurethane catalysts |
| Acetonitrile (HPLC & Spec Grade) | Specialty Chemicals | Analytical chromatography, pharmaceutical processing, peptide synthesis |
| Aliphatic Amine Derivatives & Salts | Amine Derivatives | Custom pharmaceutical intermediates, surfactant actives, fine chemical synthesis |
The commercial success of these product portfolios is supported by dedicated client partnerships, customized delivery configurations (including bulk road tankers and specialized pressure vessels), and rigorous compliance with global REACH registration requirements.
Mapping the Domestic & Global Reach (India vs. Exports)
The company maintains a strong geographic footprint, catering to 21 states domestically across India while expanding its export footprint across 39 countries globally. Exports contribute significantly to corporate turnover, shielding the business from localized cyclical demand variations.
| Geographic Market | FY 2025-26 Revenue (₹ Crores) | FY 2024-25 Revenue (₹ Crores) | % Share of FY 2025-26 Sales | Latest YoY (%) |
|---|---|---|---|---|
| India (Domestic Market) | 1,169.24 | 1,184.20 | 77.34% | -1.26% |
| Overseas (Export Markets) | 342.64 | 364.00 | 22.66% | -5.87% |
| Total Net Product Sales | 1,511.88 | 1,548.20 | 100.00% | -2.35% |
Total foreign exchange earnings on an FOB export basis reached ₹318.61 Crores in FY 2025-26 (compared to ₹343.09 Crores in FY 2024-25), with key export markets spanning North America, Europe, East Asia, and the Middle East.
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
Alkyl Amines has methodically developed a strategic physical footprint spanning advanced manufacturing complexes, captive renewable energy generation facilities, and a dedicated corporate R&D center.
- Kurkumbh Manufacturing Site (Maharashtra): Located at Plot No. D-6/1 & D-6/2, MIDC Kurkumbh Industrial Area, Taluka Daund, District Pune. Features integrated amines synthesis, downstream derivatives production, and multi-effect evaporation/reverse osmosis zero-liquid discharge capabilities. The site incorporates 94,731 sq. meters of green belt containing over 17,342 planted trees.
- Patalganga Manufacturing Site (Maharashtra): Situated at Plot No. A-7 & A-25, MIDC Patalganga Industrial Area, Village Kaire, Taluka Khalapur, District Raigad. Dedicated to aliphatic amines, specialty amines, and campaign derivative chemistries with 5,010 sq. meters of developed green belt.
- Dahej Manufacturing Site (Gujarat): Positioned at Plot No. D-2/CH/149/2 and D-2/CH/149/1/2, GIDC Dahej-2 Industrial Area, Taluka Vagra, District Bharuch. Anchors large-scale continuous aliphatic amines production, high-grade acetonitrile purification, and ongoing specialty chemical capital expansion projects. Holds 57,622 sq. meters of green belt across internal and contiguous leased plots.
- Research & Development Center (Hadapsar, Pune): State-of-the-art laboratory and analytical testing complex equipped with advanced reaction engineering and chromatography systems focusing on catalyst life extension, continuous process intensification, and new specialty molecule development.
- Captive Solar Generation Installations: 3 operating solar power generation sites situated at Bhoom (District Osmanabad, Maharashtra), Manwath (District Parbhani, Maharashtra), and Talegadh (District Banaskantha, Gujarat), supplying renewable power directly to manufacturing assets.
- Corporate & Registered Administrative Hubs: Registered Office situated at Vashi, Navi Mumbai; Corporate Office situated at Worli, Mumbai.
📊 The Financial Health: Alkyl Amines Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
A multi-year analysis across the five-year historical reporting continuum demonstrates Alkyl Amines’ consistent operating earnings, disciplined working capital management, and steady accumulation of shareholder equity.
| Financial Performance Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Gross Revenue | 1,705.80 | 1,741.98 | 1,600.58 | 1,865.15 | 1,710.43 | -2.08% |
| Net Sales | 1,535.86 | 1,571.82 | 1,419.00 | 1,656.89 | 1,523.61 | -2.29% |
| EBIDTA | 316.30 | 320.89 | 265.79 | 357.05 | 340.15 | -1.43% |
| Profit Before Tax (PBT) | 243.47 | 248.64 | 202.47 | 308.56 | 302.11 | -2.08% |
| Profit After Tax (PAT) | 180.00 | 186.11 | 148.87 | 228.66 | 224.90 | -3.28% |
| Net Fixed Assets | 1,145.60 | 1,096.42 | 1,124.80 | 1,071.19 | 771.59 | +4.49% |
| Net Current Assets | 456.90 | 384.96 | 215.44 | 146.47 | 209.66 | +18.69% |
| Equity Share Capital | 10.24 | 10.24 | 10.23 | 10.23 | 10.22 | 0.00% |
| Reserves & Surplus / Other Equity | 1,523.13 | 1,392.25 | 1,256.91 | 1,158.70 | 979.58 | +9.40% |
| Book Value Per Share (₹) | 299.81 | 274.26 | 247.87 | 228.75 | 193.80 | +9.32% |
| Basic Earnings Per Share (₹) | 35.20 | 36.40 | 29.13 | 44.75 | 44.04 | -3.30% |
| Return on Capital Employed (%) | 12.68% | 14.24% | 15.39% | 23.76% | 28.80% | – |
| Return on Net Worth (%) | 11.74% | 13.27% | 11.75% | 19.56% | 22.72% | – |
| Equity Dividend Payout (%) | 500% | 500% | 500% | 500% | 500% | – |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
The Statement of Profit and Loss reflects resilient performance amidst severe global supply chain bottlenecks and temporary input shortages caused by Middle Eastern geopolitical unrest during the fiscal year.
| Financial Line Item (Ind AS Schedule III) | FY 2025-26 (₹ Crores) | FY 2024-25 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 1,535.86 | 1,571.82 | -2.29% |
| Other Income | 31.65 | 29.80 | +6.21% |
| Total Income | 1,567.51 | 1,601.62 | -2.13% |
| Cost of Materials Consumed | 790.88 | 834.38 | -5.21% |
| Changes in Inventories of Finished Goods and Work-in-Progress | 28.42 | 4.40 | +545.91% |
| Employee Benefits Expense | 110.16 | 103.55 | +6.38% |
| Finance Costs | 1.17 | 1.01 | +15.84% |
| Depreciation and Amortization Expenses | 71.66 | 71.24 | +0.59% |
| Other Expenses | 321.75 | 338.40 | -4.92% |
| Total Expenses | 1,324.04 | 1,352.98 | -2.14% |
| Profit Before Tax (PBT) | 243.47 | 248.64 | -2.08% |
| Current Tax Provision | 63.47 | 62.53 | +1.50% |
| Profit After Tax (PAT) for the Year | 180.00 | 186.11 | -3.28% |
| Other Comprehensive Income / (Loss) (Net of Tax) | (0.12) | (1.37) | -91.24% |
| Total Comprehensive Income for the Year | 179.88 | 184.74 | -2.63% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
The company maintains a strong balance sheet characterized by a virtually debt-free capital structure, zero long-term funded bank borrowings, and substantial retained earnings funding continuous capital programs.
| Balance Sheet Items (Ind AS Schedule III) | As at March 31, 2026 (₹ Crores) | As at March 31, 2025 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Non-Current Assets | |||
| Property, Plant and Equipment | 984.31 | 1,012.50 | -2.78% |
| Capital Work-in-Progress (CWIP) | 130.48 | 51.91 | +151.36% |
| Right of Use Assets | 27.91 | 28.88 | -3.36% |
| Other Intangible Assets | 2.91 | 3.12 | -6.73% |
| Non-Current Financial Assets – Loans | 0.06 | 0.11 | -45.45% |
| Non-Current Financial Assets – Other Financial Assets | 28.06 | 3.98 | +605.03% |
| Non-Current Tax Assets (Net) | 2.10 | 7.35 | -71.43% |
| Other Non-Current Assets | 46.84 | 50.88 | -7.94% |
| Total Non-Current Assets | 1,222.67 | 1,158.73 | +5.52% |
| Current Assets | |||
| Inventories | 122.13 | 164.78 | -25.88% |
| Current Financial Assets – Investments | 50.59 | 0.00 | N/M |
| Current Financial Assets – Trade Receivables | 230.50 | 230.65 | -0.07% |
| Cash and Cash Equivalents | 94.15 | 48.78 | +93.01% |
| Bank Balances Other Than Cash and Cash Equivalents | 107.55 | 155.28 | -30.74% |
| Current Financial Assets – Loans | 0.05 | 0.08 | -37.50% |
| Current Financial Assets – Other Financial Assets | 3.29 | 3.48 | -5.46% |
| Other Current Assets | 64.49 | 27.07 | +138.23% |
| Total Current Assets | 672.75 | 630.12 | +6.77% |
| TOTAL ASSETS | 1,895.42 | 1,788.85 | +5.96% |
| EQUITY AND LIABILITIES | |||
| Equity | |||
| Equity Share Capital | 10.24 | 10.24 | 0.00% |
| Other Equity | 1,523.13 | 1,392.25 | +9.40% |
| Total Equity (Net Worth) | 1,533.37 | 1,402.49 | +9.33% |
| Non-Current Liabilities | |||
| Non-Current Borrowings | 0.00 | 0.00 | N/M |
| Non-Current Lease Liabilities | 0.39 | 1.19 | -67.23% |
| Long-Term Provisions | 14.10 | 11.66 | +20.93% |
| Deferred Tax Liabilities (Net) | 98.32 | 88.01 | +11.71% |
| Government Grant – Non Current | 32.40 | 39.55 | -18.08% |
| Non-Current Liabilities for Tax (Net) | 0.97 | 0.81 | +19.75% |
| Total Non-Current Liabilities | 146.18 | 141.22 | +3.51% |
| Current Liabilities | |||
| Current Borrowings (Cash Credit Repayable on Demand) | 0.00 | 3.60 | -100.00% |
| Current Lease Liabilities | 0.80 | 0.73 | +9.59% |
| Trade Payables: Micro and Small Enterprises | 15.50 | 14.27 | +8.62% |
| Trade Payables: Other than Micro and Small Enterprises | 135.70 | 162.97 | -16.73% |
| Current Other Financial Liabilities | 44.47 | 44.65 | -0.40% |
| Short-Term Provisions | 2.28 | 3.62 | -37.02% |
| Government Grant – Current | 5.22 | 4.82 | +8.30% |
| Other Current Liabilities | 11.88 | 10.50 | +13.14% |
| Total Current Liabilities | 215.85 | 245.16 | -11.96% |
| Total Liabilities | 362.03 | 386.38 | -6.30% |
| TOTAL EQUITY AND LIABILITIES | 1,895.42 | 1,788.85 | +5.96% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
Working capital management remained stable during the period, supported by lower average inventory holdings and prompt realization of export and domestic receivables.
| Statutory Ratio (Schedule III) | FY 2025-26 | FY 2024-25 | YoY Variance (%) | Management Statutory Explanation |
|---|---|---|---|---|
| Current Ratio (times) | 3.12 | 2.57 | +21% | Increase in liquid financial investments and reduction in trade payables. |
| Debt-Equity Ratio (times) | 0.00 | 0.00 | 0% | Zero external funded bank borrowings. |
| Debt Service Coverage Ratio (times) | 44.79 | 103.88 | -57% | Unfavourable variance due to repayment of working capital borrowings and lease payments. |
| Return on Equity Ratio (%) | 12.26% | 13.94% | -12% | Modest contraction in net profit after tax amidst geopolitical ammonia shortages. |
| Inventory Turnover Ratio (times) | 8.97 | 7.71 | +16% | Disciplined inventory optimization across finished chemical inventory. |
| Trade Receivables Turnover Ratio (times) | 7.54 | 7.69 | -2% | Consistent realization timeline averaging 60 days. |
| Trade Payables Turnover Ratio (times) | 6.81 | 6.19 | +10% | Timely vendor payment execution across critical raw material suppliers. |
| Net Capital Turnover Ratio (times) | 3.59 | 5.15 | -30% | Unfavourable variance due to an increase in current assets (liquid investments and advances). |
| Net Profit Margin (%) | 180.00 | 12.02% | -1% | Resilient operating pricing power despite input cost fluctuations. |
| Return on Capital Employed (%) | 14.98% | 16.69% | -10% | Capital additions to CWIP ahead of specialty chemical commercialization. |
Cash Flow: Tracking the Money Movement
Cash generation remained robust during FY 2025-26, enabling the company to fund capital expenditure programs internally, retire working capital lines, and maintain substantial cash balances.
| Cash Flow Summary Line Item | FY 2025-26 (₹ Crores) | FY 2024-25 (₹ Crores) | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities | 228.45 | 258.10 | -11.49% |
| Purchase of Property, Plant and Equipment (CapEx / CWIP Additions) | 121.47 | 42.90 | +183.15% |
| Investments in Mutual Funds / Fixed Deposits Placed (Net) | (10.75) | (155.28) | -93.08% |
| Net Cash Generated from / (Used in) Investing Activities | (129.94) | (190.45) | -31.77% |
| Dividends Paid to Equity Shareholders | (51.14) | (51.13) | +0.02% |
| Repayment of Short-Term Working Capital Borrowings / Lease Payments | (4.47) | (1.22) | +266.39% |
| Net Cash Used in Financing Activities | (53.14) | (53.25) | -0.21% |
| Net Increase / (Decrease) in Cash & Cash Equivalents | 45.37 | 14.40 | +215.07% |
| Cash & Cash Equivalents at End of the Year | 94.15 | 48.78 | +93.01% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
The company maintains high capital reinvestment standards to maintain plant efficiency, safety infrastructure, and continuous capacity debottlenecking across its manufacturing network.
- Capital Expenditure & CWIP Deployment: Capital work-in-progress increased to ₹130.48 Crores as of March 31, 2026 (from ₹51.91 Crores in FY 2024-25), driven by the specialty chemical project under execution at Dahej, which is scheduled for commercial commissioning in early Q2 FY 2026-27.
- Research & Development Expenditure: Total R&D expenditure reached ₹9.60 Crores in FY 2025-26, comprising ₹9.07 Crores in revenue operational expenditure and ₹0.53 Crores in capital additions, representing 0.63% of corporate turnover. Key R&D breakthroughs included the commercialization of an advanced purification process for high-grade specialty products and the development of continuous catalyst recycling systems.
- Foreign Exchange Balance: Total foreign exchange earned through direct export sales amounted to ₹318.61 Crores in FY 2025-26. Total foreign exchange outgo utilized for raw material imports, capital equipment, and overseas expenditures totaled ₹137.57 Crores, generating a net positive foreign exchange surplus of ₹181.04 Crores.
👥 Power & Control: Alkyl Amines Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The company is governed by a 10-member Board of Directors that maintains an optimal balance between promoter executive leadership and diverse independent directors with specialized industry, technical, legal, and financial expertise.
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Yogesh M. Kothari | Chairman & Managing Director | 00010015 | Executive / Promoter |
| Kirat M. Patel | Executive Director | 00019239 | Executive Director |
| Suneet Y. Kothari | Executive Director | 00021421 | Executive / Promoter Group |
| Rakesh Goyal | Whole-time Director – Operations | 07977008 | Executive Director |
| Premal N. Kapadia | Non-Executive Director | 00042090 | Non-Executive / Non-Independent |
| Leja S. Hattiangadi | Independent Director | 00198720 | Non-Executive / Independent |
| Chandrashekhar R. Gupte | Independent Director | 00009815 | Non-Executive / Independent |
| Ravi B. Kapoor | Independent Director | 01761752 | Non-Executive / Independent |
| Ashwin Ramanathan | Independent Director | 08543918 | Non-Executive / Independent |
| Bhavna G. Doshi | Independent Director | 00400508 | Non-Executive / Independent |
| Kanchan A. Shinde | Chief Financial Officer (CFO) | — | Key Managerial Personnel |
| Chintamani D. Thatte | GM (Legal) & Company Secretary | — | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
The shareholding structure of the company demonstrates high promoter commitment, coupled with institutional backing from domestic mutual funds and foreign portfolio investors.
| Category of Shareholder | Number of Shares Held | % of Total Issued Capital |
|---|---|---|
| Promoter & Promoter Group | 3,68,47,268 | 72.05% |
| Domestic Institutional Investors (Mutual Funds & AIFs) | 15,16,422 | 2.96% |
| Foreign Portfolio Investors (FPIs) | 17,66,128 | 3.45% |
| Insurance Companies & Banks | 25,448 | 0.05% |
| General Public, Bodies Corporate, IEPF & Others | 1,09,88,786 | 21.49% |
| Total Issued Share Capital | 5,11,44,052 | 100.00% |
Key individual shareholdings include Chairman & Managing Director Yogesh M. Kothari holding 2,94,79,853 equity shares (57.64%), Niyoko Trading & Consultancy LLP holding 19,58,500 shares (3.83%), Purjeeko Trading & Consultancy LLP holding 19,48,330 shares (3.81%), and Mrs. Nini Yogesh Kothari holding 12,67,870 shares (2.48%).
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
The company maintains no subsidiary, associate, or joint venture entities. Consequently, Form AOC-1 disclosure is not applicable, and all corporate operations are executed directly by the standalone operating company.
| Entity Name | Relationship | Country of Incorporation | % Equity Shareholding | Operating Turnover (₹ Crores) | Profit / (Loss) After Tax (₹ Crores) |
|---|---|---|---|---|---|
| Alkyl Amines Chemicals Limited does not hold any subsidiary, associate, or joint venture companies. | |||||
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
Alkyl Amines maintains a highly liquid treasury reserve, active consortium bank lines, and prudent management of legal and regulatory tax matters.
- Short-Term Arbitrage Investments: As of March 31, 2026, the company held ₹50.59 Crores in liquid unquoted arbitrage mutual fund schemes (DSP, Invesco India, SBI, and Tata Arbitrage Funds) marked to fair value through profit or loss.
- Credit Ratings: Credit rating agency CRISIL Limited reaffirmed the company’s credit profile at AA-/Stable for long-term working capital facilities and A1+ for short-term banking limits, reflecting superior financial flexibility and strong operational standing.
- Consortium Banking Relationships: The company maintains secured working capital limits aggregating ₹138.38 Crores with a consortium of commercial banks comprising State Bank of India, Standard Chartered Bank, Citibank, and Axis Bank. The facilities are secured by hypothecation of inventories, receivables, and second charges on manufacturing properties.
- Contingent Liabilities (Claims Not Acknowledged as Debt): Outstanding disputed matters totaled ₹36.84 Crores as of March 31, 2026 (compared to ₹36.18 Crores in FY 2024-25). These comprise disputed customs duty matters of ₹14.05 Crores (supported by ₹2.50 Crores deposited under protest), disputed central excise claims of ₹12.16 Crores (supported by ₹0.21 Crores deposited under protest), income tax assessments under appeal totaling ₹10.18 Crores, and labour disputes of ₹0.45 Crores.
- Capital Commitments: Estimated amount of capital contracts remaining to be executed (net of capital advances of ₹9.16 Crores) stood at ₹23.01 Crores as of March 31, 2026.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Alkyl Amines has methodically constructed distinct economic barriers that shield its core chemical synthesis franchises:
- Proprietary Catalytic Know-How: Proprietary in-house catalyst synthesis and reactor engineering enable superior raw material conversion ratios, lower reaction temperatures, and high selectivity towards desired amine isomers.
- Integrated Supply Chain & Handling Infrastructure: Anhydrous ammonia and low-boiling alkylamines require specialized pressurized transportation, cryogenic bulk storage, and dedicated safety handling systems that present high entry barriers to prospective market entrants.
- Broad Multi-Product Manufacturing Footprint: Operating across three interconnected chemical manufacturing sites in Maharashtra and Gujarat enables multi-product campaign scheduling, operational redundancy, and proximity to major downstream pharmaceutical clusters.
- Environmental Stewardship & ZLD Operations: Full zero-liquid discharge capabilities and high green-belt coverage across sites provide regulatory resilience and protect long-term operating licenses.
What Could Go Wrong? Key Challenges & Business Risks
The company’s operations remain exposed to cyclical external headwinds:
- Geopolitical Supply Chain Shocks: Disruptions in Middle Eastern energy networks and liquefied natural gas (LNG) availability can restrict raw material ammonia supply, leading to temporary force majeure declarations and curtailment of production runs.
- Aggressive Chinese Export Pricing: Global merchant dumping of chemical intermediates—such as acetonitrile—by large-scale Chinese producers can exert downward pressure on realizations and compress gross spreads.
- Raw Material Price Volatility: Denatured ethyl alcohol and petroleum-derived methanol feedstocks remain subject to seasonal sugarcane agricultural cycles and crude oil benchmark swings.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
The forward strategic roadmap focuses on commissioning high-value specialty chemical capacities at Dahej in early Q2 FY 2026-27, enhancing green hydrogen and renewable solar integration, and leveraging anti-dumping duty protections implemented on acetonitrile to regain domestic market share.
Management continues to invest in continuous process development, exploring continuous flow chemistry for legacy batch operations, and expanding high-purity solvent grades tailored for high-growth oligonucleotide and biotech therapeutics manufacturing.
The Verdict: Strategic Outlook & Conclusion
Alkyl Amines Chemicals Limited enters FY 2026-27 with a robust, debt-free balance sheet, ₹201.70 Crores in liquid cash and bank reserves, a high return on capital framework, and steady operating margins. By pairing technical manufacturing depth with disciplined capital deployment, the enterprise remains well-positioned to benefit from the global realignment of specialty chemical supply chains toward high-quality Indian manufacturers.
Frequently Asked Questions (FAQs) About Alkyl Amines
Q1: What does Alkyl Amines Chemicals Limited manufacture and what are its key products?
Alkyl Amines manufactures aliphatic amines (such as Methylamines and Ethylamines), downstream amine derivatives, high-purity Acetonitrile, and fine specialty chemical intermediates used in pharmaceuticals, agrochemicals, water treatment, and rubber processing industries.
Q2: What were Alkyl Amines’ revenue and net profit in FY 2025-26?
In FY 2025-26, the company generated Revenue from Operations of ₹1,535.86 Crores, a Profit Before Tax of ₹243.47 Crores, and a Net Profit After Tax of ₹180.00 Crores.
Q3: Who are the key promoters and executive leadership of Alkyl Amines?
The company is led by industrialist Yogesh M. Kothari, who serves as Chairman and Managing Director. Executive leadership includes Executive Director Kirat M. Patel, Executive Director Suneet Y. Kothari, and Whole-time Director – Operations Rakesh Goyal.
Q4: Where are the manufacturing plants located and what is the export share?
Alkyl Amines operates three chemical production sites at Kurkumbh and Patalganga in Maharashtra, and Dahej in Gujarat, supported by three captive solar plants. Export markets across 39 countries contributed ₹342.64 Crores, or 22.66% of net sales, in FY 2025-26.
Q5: What is Alkyl Amines’ debt profile, credit rating, and net worth?
The company operates with zero long-term funded debt, supported by a strong Net Worth of ₹1,533.37 Crores as of March 31, 2026. CRISIL Limited rates its bank facilities at AA-/Stable (long-term) and A1+ (short-term).
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.alkylamines.com